Purchases and Sales Made in Q3 2023 in Lineage Cell Therapeutics, Inc. (LCTX)
This table provides information about the institutional ownership of Lineage Cell Therapeutics, Inc. (LCTX) during Q3 2023. The information is specifically focused on institutions that hold shares of Lineage Cell Therapeutics, Inc..
| Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
|---|---|---|---|---|---|---|---|
|
Nov 09, 2023
Q3 2023
|
Citigroup Inc
|
SELL
|
- |
-25.7K- 16.2% |
$29.8K - $39.4K
|
133K
$66.5K
|
|
|
Nov 13, 2023
Q3 2023
|
Wells Fargo & Company
San Francisco, CA |
SELL
|
- |
-27.7K- 34.67% |
$32.1K - $42.4K
|
52.2K
$26.1K
|
|
|
Nov 07, 2023
Q3 2023
|
New York State Common Retirement Fund
|
SELL
|
- |
-64K- 94.74% |
$74.3K - $98K
|
3.56K
$1.78K
|
|
|
Nov 13, 2023
Q3 2023
|
Connor, Clark & Lunn Investment Management Ltd.
|
SELL
|
- |
-70.7K- 27.92% |
$82K - $108K
|
183K
$91.3K
|
|
|
Nov 14, 2023
Q3 2023
|
D. E. Shaw & Co., Inc.
New York, NY |
SELL
|
- |
-71.5K- 58.25% |
$82.9K - $109K
|
51.2K
$25.6K
|
|
|
Nov 14, 2023
Q3 2023
|
Jpmorgan Chase & CO
New York, NY |
SELL
|
- |
-331K- 31.81% |
$384K - $506K
|
709K
$355K
|